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Abstract: Adamantyl-based compounds are commercially important in the treatments for 
neurological conditions and type-2 diabetes, aside from their anti-viral abilities. Their 
values in drug design are chronicled as multi-dimensional. In the present study, a series of 
2-(adamantan-1-yl)-2-oxoethyl benzoates, 2(a–q), and 2-(adamantan-1-yl)-2-oxoethyl  
2-pyridinecarboxylate, 2r, were synthesized by reacting 1-adamantyl bromomethyl ketone 
with various carboxylic acids using potassium carbonate in dimethylformamide medium at 
room temperature. Three-dimensional structures studied using X-ray diffraction suggest 
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that the adamantyl moiety can serve as an efficient building block to synthesize  
2-oxopropyl benzoate derivatives with synclinal conformation with a looser-packed crystal 
packing system. Compounds 2a, 2b, 2f, 2g, 2i, 2j, 2m, 2n, 2o, 2q and 2r exhibit strong 
antioxidant activities in the hydrogen peroxide radical scavenging test. Furthermore,  
three compounds, 2p, 2q and 2r, show good anti-inflammatory activities in the evaluation 
of albumin denaturation. 
Keywords: adamantyl; synclinal; crystal packing; antioxidant; anti-inflammatory 
 
1. Introduction 
Adamantane is the simplest diamondoid with a chemical formula of C10H16. It consists of four 
cyclohexane rings in an armchair configuration. To date, seven adamantane derivatives have been 
applied in clinical usage to treat acne vulgaris [1], Alzheimer’s disease [2], as an anti-viral [3–7] and 
for type-2 diabetes [8–10], while the others are in development as potential therapeutics for iron 
overload disease, neurological conditions, malaria, tuberculosis and cancers [11]. Previous studies on 
adamantyl-based compounds revealed their antioxidant and anti-inflammatory properties [12–14]. As a 
reactive oxygen species, hydrogen peroxide is generated as a by-product of biological reaction. These 
reactive species will cause oxidative damaging effects in living cells. Hydrogen peroxide acts as a 
weak oxidizing agent and reacts with Fe2+ or Cu2+ ions to form the hydroxyl radical [15]. Similarly, 
free radicals, such as DPPH (2,2-diphenyl-1-picrylhydrazyl), are readily attacked and promote oxidative 
damage of biomolecules, such as lipids, proteins and DNA, leading to many human pathological 
conditions [16,17]. On the other hand, failure in the downregulation of pro-inflammatory mediators will 
result in an imbalance between inflammation and its regulation, which leads to chronic inflammation 
due to excessive macrophage responses. The resulting disease conditions from chronic inflammation 
include asthma, rheumatic arthritis, atherosclerosis and cancer [18]. Protection against protein denaturation, 
a well-documented phenomenon caused by the inflammation process, is the main consideration in 
developing non-steroidal anti-inflammatory drugs (NSAIDs) [19]. 
Encouraged by the biological activities of adamantane derivatives, we herein present FTIR, 1H-NMR 
and 13C-NMR spectra and single-crystal X-ray diffraction analysis of some new adamantyl-based ester 
derivatives. Using a group comparison of single-crystal X-ray diffraction data, the structural conformation, 
structural occupancy and crystal packing similarity were studied. Their antioxidant activities were 
evaluated by hydrogen peroxide and the DPPH radical scavenging assay. In addition, the anti-inflammatory 
activity of these adamantyl-based ester derivatives was determined by the protein denaturation assay. 
2. Results and Discussion 
The full reaction involved the synthesis of 1-adamantyl bromomethyl ketone, 1, which is essential for 
subsequent synthesis of 2(a–r) in accordance with the reported procedure [20], as shown in Scheme 1. 
The structures of the intermediate and final compounds were elucidated by various spectral techniques, 
like FTIR, 1H-NMR, 13C-NMR and single-crystal X-ray diffraction analysis. The asymmetric and 
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symmetric stretchings of the methyl group (asym 2960 cm−1: sym 2870 cm−1) in 1 had changed to 
methylene stretchings (asym 2920 cm−1: sym 2850 cm−1); however, the synthesis of 1 is confirmed by 
1H-NMR when the peak corresponding to the methyl group of 1-adamantyl methyl ketone is replaced by 
the peak corresponding to the methylene group near δ 4.1 ppm. Esterification of 2(a–r) was confirmed 
by FTIR, where the peak corresponding to the hydroxyl of carboxylic acid disappeared. Furthermore, 
some peaks were observed at ~1300 cm−1–1020 cm−1, which corresponded to C—O stretching of ester. 
Similarly, the 1H-NMR of 2(a–r) displays a singlet corresponding to the methylene group at higher 
chemical shifts (δ 5.1 ppm) associated with the other required aromatic peaks. In the FTIR spectra of 
2(a–r), the exceptional and predictable observations are the occurrences of N=O stretching in 2(l–m) 
and the N—H stretching in 2(o–q) at ~1530 cm−1 and ~3490 cm−1, respectively; whereas for 13C-NMR, 
the constant appearances of carbonyl carbons peaks at 207 and 165 ppm further support the formation 
of the ester bond in Compounds 2(a–r). The crystal structure for all compounds, except 2m and 2q, 
were determined by single-crystal X-ray diffraction analysis. All spectra, crystallography data and crystal 
packing are described in detail in the Supplementary Data. 
 
Scheme 1. Reaction scheme for 2(a–r). 
2.1. General Description of the Crystal Structure Conformations 
The asymmetric unit (Z′) of the studied compounds consists of either one (2c, 2d, 2g, 2h, 2j, 2k, 
2n–p and 2r) or two (2a, 2b, 2e, 2f, 2i and 2l) crystallographic independent molecules. For a crystal 
with Z′ = 2, the independent molecules are hereafter denoted as Molecules A and B, respectively. The 
orientational disorder of the adamantane group is observed in 2a, 2b, 2f, 2j, 2l and 2o with a refined  
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site occupancy ratio, as summarized in the table below (Table 1). All disordered components of 
adamantane are rotationally-related, and in particular, two-fold rotation disorder (ca. 180°) is observed  
in 2a (Molecule B) and 2f (Molecule B). 
Table 1. Refined site occupancy ratio for disordered compounds. 
Compound Refined Site Occupancy Ratio 
2a 
0.390 (10):0.610 (10) (A) 
0.695 (4):0.305(4) (B) 
2b 0.431 (10):0.569 (10) (A) 
2f 
0.716 (6):0.284 (6) (A) 
0.793 (4):0.207 (4) (B) 
2j 0.753 (3):0.247 (3) 
2l 0.873 (4):0.127 (4) (B) 
2o 0.897 (4):0.103 (4) 
Molecular conformation of these compounds can be characterized by three degrees of freedom, which 
are the torsion angles of C1—C8—C11—O2 (τ1), C11—C12—O1—C13 (τ2) and O1—C13—C14—C15 
(τ3) (Figure 1). Although the torsion angle between the adamantane moiety and the adjacent carbonyl 
group (C1—C8—C11—O2, τ1) is one of the degrees of freedom, it was irrelevant for the comparison 
due to its randomness and the effect of disordered orientations. By referring to the previous report [20], 
torsion angle τ2, which interconnects two carbonyl groups, tends to adopt two types of conformations, 
either synclinal or periplanar. However, all structures reported in this study adopt only one conformation 
in which τ2 torsion angles are all in synclinal conformation ranging from 70°–86°, which may be due to 
the introduction of the bulky adamantane moiety. The range of the O1—C13—C14—C15 τ3 torsion 
angle, which defines the twisted angle between the carboxylate group and the six-membered ring,  
is relatively larger compared to τ2, ranging from 1.25°–39.08° and 126.4°–179.57°. In compounds 2e  
(2,4-dichlorobenzene), 2i (2-methoxybenzene) and 2l (2-nitrobenzene), the τ3 is probably induced by the 
steric repulsion between the o-substituent and the adjacent carbonyl oxygen atom. Nevertheless, 
exceptional cases are observed in 2b (2-chlorobenzene), 2f (2-methylbenzene) and 2o (2-aminobenzene) 
with small deviations of 3.78°, 11.55°, 6.64°, 9.58° and 8.08° from perfect planarity. The amino 
substituent at the -ortho position (2o) forms a strong intramolecular N—H···O hydrogen bond with the 
adjacent carbonyl group to improve the planarity of the benzoate group (τ3 = 171.92°). Torsion angles 
between two carbonyl group (C11—C12—O1—C13, τ2) and torsion angles between the carbonyl group 
with its adjacent benzene ring (O1—C13—C14—C15, τ3) of the reported compounds are summarized in 
Table 2. 
 
Figure 1. General chemical scheme for all compounds, showing τ1, τ2 and τ3 as torsion angles. 
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Table 2. Summary of the C11—C12—O1—C13 and O1—C13—C14—C15 torsion angles. 
Compound Substituent 
Torsion Angles  
C11—C12—O1—C13, τ2 
Torsion Angles  
O1—C13—C14—C15, τ3 
2a Benzene −81.31, 75.84 −9.95, 2.84 
2b 2-Chlorobenzene 78.96, 75.23 11.55, −3.78 
2c 3-Chlorobenzene 73.10 3.22 
2d 4-Chlorobenzene 73.75 −179.57 
2e 2,4-Dichlorobenzene −69.7, −85.50 138.13, 135.26 
2f 2-Methylbenzene −76.09, 77.77 −9.58, 6.64 
2g 3-Methylbenzene −72.91 1.25 
2h 4-Methylbenzene 75.42 −170.83 
2i 2-Methoxybenzene −86.12, −79.34 39.08, 156.87 
2j 3-Methoxybenzene −75.05 −173.58 
2k 4-Methoxybenzene −76.60 168.36 
2l 2-Nitrobenzene −70.96, −70.23 126.4, 130.00 
2n 4-Nitrobenzene 73.57 −1.86 
2o 2-Aminobenzene −76.5 171.92 
2p 3-Aminobenzene 77.13 −17.86 
2r 2-Pyridine −75.07 −17.79, 22.32 
2.2. Structural Occupancy and Crystal Packing Similarity 
Sixteen present adamantyl-based ester derivatives and thirty-six reported phenacyl benzoate derivatives, 
which are found from the Cambridge Structure Database (CSD 5.35) search, are compared to each 
other in order to identify the effect of the replacement of the electron-rich phenyl ring (search result) 
with the bulky adamantane moiety (present compounds) or vice versa on the molecular conformation 
and structural occupancy. In the aspect of molecular conformation, it is noteworthy to observe that 
neither periplanar conformation nor mixed (periplanar and synclinal) conformation is adopted by the 
currently studied compounds, unlike the variations displayed in phenacyl benzoates. All present 
compounds adopt synclinal conformation with C13—O1—C12—C11 torsion angles falling in the 
range from 69.7°–86.12°, which is comparable to those previously reported for phenacyl benzoate 
derivatives that adopt the same conformation (71°–91°) [20]. The structural occupancies of all present 
and reported compounds are listed in Table 3. The structural occupancy of phenacyl benzoate derivatives 
has a larger range compared to adamantyl-based ester derivatives and is mostly in between 63% and 
69% (30 out of 36). All of the present adamantyl-based compounds are below this range, except 2n 
(Figure 2). The existence of the adamantane moiety in the present compounds not only reduces the weak 
intermolecular π…π or C—H…π interactions as compared to phenacyl benzoates, it also limits the packing 
patterns of adamantyl-based ester derivatives as indicated by the high occurrence of isostructures. 
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Table 3. List of the structural occupancy of the present and reported compounds i. 
Compound 
Packing 
Coefficient (%) 
Compound 
Packing 
Coefficient (%) 
Compound 
Packing 
Coefficient (%) 
2a 61.11 CIXVUC [20] 63.94 GITHUN [21] 64.40 
2b 61.32 CIXWAJ [20] 64.33 MANGIR [22] 61.06 
2c 62.33 CIXWEN [20] 62.08 OBOYIP [23] 67.22 
2d 62.53 CIXWIR [20] 63.98 OCAKUA [24] 63.92 
2e 60.79 CIYCAQ [20] 67.27 OCAQUG [25] 66.98 
2f 60.97 CIYCEU [20] 65.07 OCEFEJ [26] 68.55 
2g 61.68 CIYCIY [20] 68.83 PECZAA [27] 64.37 
2h 61.02 CIYCOE [20] 62.96 PODQIK [28] 60.66 
2i 61.58 CIYFUN [20] 62.38 PODRAD [29] 63.77 
2j 61.08 CIYGAU [20] 64.89 USIWID [30] 62.53 
2k 61.07 EVAFOX [31] 68.00 USIWOJ [32] 66.04 
2l 61.85 EVAJAN [33] 65.64 VOBYUI [34] 63.97 
2n 63.05 EVAJIV [35] 64.03 YAFWEJ [36] 66.25 
2o 61.24 EVAZEH [37] 63.03 YAFZAI [38] 68.65 
2p 61.81 EVEGIW [39] 63.25 YAHGUL [40] 63.55 
2r 60.61 EVEGOC [41] 63.22 YAHYOX [42] 63.37 
AZULUD [43] 63.85 EVEVEH [44] 63.04   
CIQNEW [45] 64.07 GARCEJ [46] 65.80   
i Each reported compound is represented by the Cambridge Crystallographic Data Centre (CCDC) reference 
code, and its systematic name is provided in the Supplementary Materials. 
 
Figure 2. Structural occupancy comparison of the present and reported compounds. 
In the investigation of the crystal structural similarity among the current compounds, there are four pairs 
of compounds (2a/2f, 2c/2g, 2h/2k and 2d/2n) found, and each pair is crystallized in the same space group 
with similar lattice constants, which are two main characteristics of 3D structural similarity. Indeed, 
these four pairs of compounds show isostructural relationships with a similar packing pattern, as shown 
in their overlaid crystal structure diagrams (Figures 3–6, respectively). Besides that, 2D similarities are 
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observed in 2b/2a and 2b/2f, while Compounds 2c, 2d, 2g and 2n show 2D similarity among each 
other (Figure 7). 
 
Figure 3. Crystal packing comparison of Compounds 2a and 2f. 
 
Figure 4. Crystal packing comparison of Compounds 2c and 2g. 
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Figure 5. Crystal packing comparison of Compounds 2h and 2k. 
 
Figure 6. Crystal packing comparison of Compounds 2d and 2n. 
 
Figure 7. Crystal packing relationship in some studied compounds. Red boxes and yellow 
arrows indicate 3D and 2D similarities, respectively. 
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2.3. Antioxidant and Anti-Inflammatory Properties 
The antioxidant properties of adamantane-based compounds were determined by two methods, which 
are hydrogen peroxide and DPPH radicals scavenging abilities. The scavenging effects of hydrogen 
peroxide by the adamantyl-based compounds were evaluated at a concentration of 250 μg/mL and are 
summarized in Figure 8. Eleven adamantane derivatives show positive scavenging effects on H2O2. 
Compound 2b possesses the strongest scavenging activity, which is 48.55%, followed by Compounds 2q 
and 2g with 42.96% and 42.56%, respectively. The scavenging activities of these compounds are 
comparable to the standard compound, ascorbic acid, with an inhibition percentage of 43.38%. On the 
other hand, adamantyl-based compounds did not show positive DPPH radical scavenging properties at 
a concentration of 1000 μg/mL. The results show that adamantane derivatives are selective to the 
inhibition of hydrogen peroxide radicals. 
 
Figure 8. Hydrogen peroxide radical scavenging. The data represent the percentage of 
hydrogen peroxide radical inhibition (mean ± SD), and experiments were performed  
in triplicate. 
The anti-inflammatory effects of adamantyl-based compounds at a concentration of 250 μg/mL were 
evaluated by the protein denaturation assay. The results of the percentage of inhibition against protein 
denaturation are presented in Figure 9. Compounds 2p, 2q and 2r are strong protein denaturation 
inhibitors with inhibition percentages of 41.92%, 43.94% and 40.91%, respectively, which are better 
than the standard drug, diclofenac sodium, with an inhibition percentage of 37.88%. These three 
compounds consist of either an amino-substituted phenyl ring or a pyridine ring. Hence, the high 
inhibition effects are deduced to be the direct contribution from the nitrogen-containing group in 
adamantyl-based compounds. 
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Figure 9. Inhibition of protein denaturation. The data represent the percentage of hydrogen 
peroxide radical inhibition (mean ± SD), and experiments were performed in triplicate. 
3. Experimental Section 
The reagents and solvents for the synthesis work were obtained commercially from Sigma Aldrich 
Corporation (St. Louis, MO, USA) and used without any additional purification. Melting points were 
determined on a Stuart (Staffordshire, UK) SMP10 apparatus. 1H and 13C nuclear magnetic resonance 
(NMR) spectra were determined in CDCl3 at 500 MHz and 125 MHz, respectively, using a Bruker 
Advance III 500 spectrometer (Bruker Corporation, Billerica, MA, USA). Fourier transform infrared 
spectroscopy (FTIR) spectra were recorded on a Perkin Elmer Frontier FTIR spectrometer (PerkinElmer, 
Inc., Waltham, MA, USA) equipped with attenuated total reflection (ATR). 
The X-ray analysis for all samples was performed using a Bruker APEX II DUO CCD diffractometer 
(Bruker Corporation) employing MoKα radiation (λ = 0.71073 Å) with φ and ω scans. X-ray data for 
all compounds were collected at room temperature. Data reduction and absorption correction were 
performed using the SAINT and SADABS program [47]. All structures were solved by the direct 
method and refined by full-matrix least-squares techniques on F2 using the SHELXTL software 
package [48]. All non-hydrogen atoms were refined anisotropically, except for the minor disordered 
components of 2l and 2o with a site occupancy of less than 0.2. The C-bound H atoms were calculated 
geometrically with isotropic displacement parameters set to 1.2-times the equivalent isotropic U value of 
the parent carbon atoms. N-bound H atoms are located by the difference Fourier map and refined freely 
(N—H = 0.77 (5)—0.87 (6) Å). A similar geometry restraint (SAME) was applied to the disordered 
adamantane moiety in 2f and 2o and also the full molecule in 2r. Packing coefficient (%)/structure 
occupancy was calculated using the Olex2 program with the command (-calcvoid) [49]. Crystallographic 
data for the structures reported in this paper (2a–r, excluding 2m and 2q) have been deposited with the 
Cambridge Crystallographic Data Centre (CCDC) as supplementary publication. CCDC 1030854–1030869 
contain the supplementary crystallographic data for this paper. These data can be obtained free of charge 
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via http://www.ccdc.cam.ac.uk/conts/retrieving.html (or from the CCDC, 12 Union Road, Cambridge 
CB2 1EZ, UK; Fax: +44 1223 336033; E-mail: deposit@ccdc.cam.ac.uk). 
3.1. Synthesis 
1-Adamantyl methyl ketone was refluxed with N-bromo succinimide and petroleum ether in methanol 
at 333 K for two hours. The resultant 1-adamantyl bromomethyl ketone (1) precipitate was filtered and 
recrystallized with ethanol. After that, 1-adamantyl bromomethyl ketone (1) (0.51 g, 0.002 mol) was 
reacted with the corresponding carboxylic acid (0.003 mol) with the presence of potassium carbonate 
in DMF (8 mL) and stirred at room temperature for about 3 h. The reaction progress was monitored by 
thin layer chromatography (TLC). After the reaction completed, the reaction mixture was poured into 
ice-cooled water and kept stirring for 10 min. The solid obtained was filtered out, washed successively 
with distilled water and recrystallized from acetone after it dried [20]. All targeted compounds were 
synthesized in good yield and high purity. Suitable single-crystal specimens were obtained from various 
types of solvents, as described below. The chemical structures were characterized by using FTIR and 
NMR spectroscopies. The crystal structures for all compounds except 2m and 2q were determined by 
single-crystal X-ray diffraction analysis. 
3.2. Spectroscopic Details 
1-Adamantyl bromomethyl ketone (1): Solvent for growing crystal: ethanol; yield: 85%; M.P. 326–328 K; 
FTIR (ATR (solid) cm−1): 2905, 2851 (C–H, ν), 1709 (C=O, ν), 1254, 1094, 1063 (C–O, ν), 733 (C–Cl, 
ν); 1H-NMR (500 MHz, CDCl3): δ ppm 4.18 (s, 2H, -CH2), 2.09 (br-s, 3H, adamantane-CH), 1.91–1.90 
(br-d, 6H, adamantane-CH2), 1.80–1.72 (br-q, 6H, adamantane-CH2); 13C-NMR (125 MHz, CDCl3):  
δ ppm 205.57 (C=O), 46.62 (-CH2), 38.53, 36.34, 31.83, 27.83 (adamantane-Cs). 
2-(Adamantan-1-yl)-2-oxoethyl benzoate (2a): Solvent for growing crystal: acetone; yield: 80%; M.P. 
374–376 K; FTIR (ATR (solid) cm−1): 2917, 2850 (C–H, ν), 1709 (C=O, ν), 1602, 1413 (Ar, C=C, ν), 
1277, 1120 (C–O, ν), 706 (C–H, ω); 1H-NMR (500 MHz, CDCl3): δ ppm 8.10–8.08 (d, 2H, J = 7.5 Hz, 
Ar), 7.58–7.55 (t, 1H, J = 7.5 Hz, Ar), 7.46–7.42 (t, 2H, J = 7.5 Hz, Ar), 5.10 (s, 2H, -CH2), 2.08(br-s, 
3H, adamantane-CH), 1.94–1.93 (br-d, 6H, adamantane-CH2), 1.80–1.72 (br-q, 6H, adamantane-CH2); 
13C-NMR (125 MHz, CDCl3): δ ppm 207.16 (C=O), 166.04 (O-C=O), 133.19, 129.87, 129.58, 128.37 
(Ar), 64.94 (-CH2), 45.39, 38.02, 36.47, 27.79 (adamantane-Cs). 
2-(Adamantan-1-yl)-2-oxoethyl 2-chlorobenzoate (2b): Solvent for growing crystal: acetone and ethanol 
(1: 1 v/v); yield: 83%; M.P. 348–350 K; FTIR (ATR (solid) cm−1): 2904, 2850 (C–H, ν), 1709 (C=O, ν), 
1590, 1416 (Ar, C=C, ν), 1247, 1024 (C–O, ν), 742 (C–Cl, ν); 1H-NMR (500 MHz, CDCl3): δ ppm 
8.01–8.00 (d, 1H, J = 8.0 Hz, Ar), 7.47–7.43 (q, 2H, J = 8.0 Hz, Ar), 7.35–7.32 (t, 1H, J = 8.0 Hz, Ar), 
5.12 (s, 2H, -CH2), 2.09 (br-s, 3H, adamantane-CH), 1.93–1.93 (br-d, 6H, adamantane-CH2), 1.80–1.72 
(br-q, 6H, adamantane-CH2); 13C-NMR (125 MHz, CDCl3): δ ppm 206.98 (C=O), 164.89 (O-C=O), 133.98, 
132.84, 131.95, 131.03, 129.35, 126.62 (Ar), 65.18(-CH2), 45.38 37.99, 36.44, 27.75 (adamantane-Cs). 
2-(Adamantan-1-yl)-2-oxoethyl 3-chlorobenzoate (2c): Solvent for growing crystal: acetone, ethanol and 
acetonitrile (1:1:1 v/v/v); yield: 73%; M.P. 403–405 K; FTIR (ATR (solid) cm−1): 2911, 2850 (C–H, ν), 
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1718 (C=O, ν), 1571, 1442 (Ar, C=C, ν), 1295, 1253, 1130 (C–O, ν), 745 (C–Cl, ν); 1H-NMR (500 MHz, 
CDCl3): δ ppm 8.07 (s, 1H, Ar), 7.98–7.96 (d, 1H, J = 8.0 Hz, Ar), 7.55–7.54 (d, 1H, J = 8.0 Hz, Ar), 
7.41–7.38 (t, 1H, J = 8.0 Hz, Ar), 5.11 (s, 2H, -CH2), 2.09 (br-s, 3H, adamantane-CH), 1.93–1.93 (br-d, 
6H, adamantane-CH2), 1.800–1.719 (br-q, 6H, adamantane-CH2); 13C-NMR (125 MHz, CDCl3): δ ppm 
206.94 (C=O), 164.88 (O-C=O), 134.56, 133.27, 131.27, 129.95, 129.73, 128.01 (Ar), 65.23(-CH2), 45.37, 
37.98, 36.43, 27.74 (adamantane-Cs). 
2-(Adamantan-1-yl)-2-oxoethyl 4-chlorobenzoate (2d): Solvent for growing crystal: acetone, ethanol and 
acetonitrile (1:1:1 v/v/v); yield: 75%; M.P. 411–413 K; FTIR (ATR (solid) cm−1): 2910, 2851 (C–H, ν), 
1723 (C=O, ν), 1593, 1421 (Ar, C=C, ν), 1269, 1119 (C–O, ν), 752 (C–Cl, ν); 1H-NMR (500 MHz, 
CDCl3): δ ppm 8.03–8.01 (d, 2H, J = 8.8 Hz, Ar), 7.43–7.41 (d, 2H, J = 8.8 Hz, Ar), 5.09 (s, 2H,  
-CH2), 2.08 (br-s, 3H, adamantane-CH), 1.93–1.92 (br-d, 6H, adamantane-CH2), 1.80–1.72 (br-q, 6H, 
adamantane-CH2); 13C-NMR (125 MHz, CDCl3): δ ppm 207.07 (C=O), 165.19 (O-C=O), 139.71, 131.27, 
128.76, 128.01 (Ar), 65.11(-CH2), 45.37, 37.99, 36.43, 27.75 (adamantane-Cs). 
2-(Adamantan-1-yl)-2-oxoethyl 2,4-dichlorobenzoate (2e): Solvent for growing crystal: acetone; yield: 
85%; M.P. 395–397 K; FTIR (ATR (solid) cm−1): 2912, 2850 (C–H, ν), 1711 (C=O, ν), 1583, 1417 
(Ar, C=C, ν), 1244, 1129, 1098, 1023 (C–O, ν), 829 (C–Cl, ν); 1H-NMR (500 MHz, CDCl3): δ ppm 
7.98–7.96 (d, 1H, J = 8.5 Hz, Ar), 7.48 (s, 1H, Ar), 7.33–7.31 (d, 1H, J = 8.5 Hz, Ar), 5.11 (s, 2H,  
-CH2), 2.09 (br-s, 3H, adamantane-CH), 1.93–1.92 (br-d, 6H, adamantane-CH2), 1.80–1.72 (br-q, 6H, 
adamantane-CH2); 13C-NMR (125 MHz, CDCl3): δ ppm 206.86 (C=O), 164.01 (O-C=O), 138.66, 
135.20, 133.00, 131.00, 127.62, 127.06 (Ar), 65.30(-CH2), 45.38, 37.98, 36.42, 27.73 (adamantane-Cs). 
2-(Adamantan-1-yl)-2-oxoethyl 2-methylbenzoate (2f): Solvent for growing crystal: acetone; yield: 
83%; M.P. 367–369 K; FTIR (ATR (solid) cm−1): 2905, 2851 (C–H, ν), 1708 (C=O, ν), 1602, 1415 
(Ar, C=C, ν), 1253, 1026 (C–O, ν), 733 (C–H, ω); 1H-NMR (500 MHz, CDCl3): δ ppm 8.02–8.00 (d, 
1H, J = 8.0 Hz, Ar), 7.42–7.39 (t, 1H, J = 8.0 Hz, Ar), 7.25–7.24 (m, 2H, Ar), 5.09 (s, 2H, -CH2),  
2.09 (br-s, 3H, adamantane-CH), 1.94–1.94 (br-d, 6H, adamantane-CH2), 1.80–1.72 (br-q, 6H, 
adamantane-CH2); 13C-NMR (125 MHz, CDCl3): δ ppm 207.41 (C=O), 166.98 (O-C=O), 140.43, 
132.19, 131.58, 130.89, 129.06, 125.72 (Ar), 64.74 (-CH2), 45.37, 38.03, 36.47, 27.78 (adamantane-Cs), 
21.60 (-CH3). 
2-(Adamantan-1-yl)-2-oxoethyl 3-methylbenzoate (2g): Solvent for growing crystal: acetone, ethanol and 
acetonitrile (1:1:1 v/v/v); yield: 75%; M.P. 372–374 K; FTIR (ATR (solid) cm−1): 2902, 2848 (C–H, ν), 
1724 (C=O, ν), 1588, 1421, (Ar, C=C, ν), 1302, 1279, 1195, 1109 (C–O, ν), 740 (C–H, ω); 1H-NMR 
(500 MHz, CDCl3): δ ppm 7.91 (s, 1H, Ar), 7.89–7.88 (d, 2H, J = 7.5 Hz, Ar), 7.39–7.37 (d, 1H,  
J = 7.5 Hz, Ar), 7.35–7.32 (t, 1H, J = 7.5 Hz Ar), 5.09 (s, 2H, -CH2), 2.08 (br-s, 3H, adamantane-CH), 
1.94–1.93 (br-d, 6H, adamantane-CH2), 1.80–1.72 (br-q, 6H, adamantane-CH2); 13C-NMR (125 MHz, 
CDCl3): δ ppm 207.32 (C=O), 166.25 (O-C=O), 138.17, 134.00, 130.39, 129.44, 128.29, 127.04 (Ar), 
64.91 (-CH2), 45.39, 38.01, 36.47, 27.78 (adamantane-Cs), 21.26 (-CH3). 
2-(Adamantan-1-yl)-2-oxoethyl 4-methylbenzoate (2h): Solvent for growing crystal: acetone; yield: 81%; 
M.P. 413–415 K; FTIR (ATR (solid) cm−1): 2902, 2853 (C–H, ν), 1714 (C=O, ν), 1610, 1418, (Ar, 
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C=C, ν), 1258, 1115, (C–O, ν), 747 (C–H, ω); 1H-NMR (500 MHz, CDCl3): δ ppm 7.98–7.97 (d, 2H,  
J = 8.0 Hz, Ar), 7.25–7.23 (d, 2H, J = 8.0 Hz, Ar), 5.08 (s, 2H, -CH2), 2.41 (s, 3H, -CH3), 2.08 (br-s, 3H, 
adamantane-CH), 1.93–1.93 (br-d, 6H, adamantane-CH2), 1.80–1.72 (br-q, 6H, adamantane-CH2);  
13C-NMR (125 MHz, CDCl3): δ ppm 207.37 (C=O), 166.12 (O-C=O), 143.93, 129.92, 129.10, 126.80 
(Ar), 64.82 (-CH2), 45.39, 38.01, 36.47, 27.79 (adamantane-Cs), 21.70 (-CH3). 
2-(Adamantan-1-yl)-2-oxoethyl 2-methoxybenzoate (2i): Solvent for growing crystal: acetone and ethanol 
(1: 1 v/v); yield: 80%; M.P. 362–364 K; FTIR (ATR (solid) cm−1): 2902, 2851 (C–H, ν), 1702 (C=O, ν), 
1599, 1442 (Ar, C=C, ν), 1248, 1096, 1020 (C–O, ν), 758 (C–H, ω); 1H-NMR (500 MHz, CDCl3): δ ppm 
7.97–7.95 (d, 1H, J = 8.5 Hz, Ar), 7.50–7.47 (t, 1H, J = 8.5 Hz, Ar), 7.01–6.97 (t, 2H, J = 8.5 Hz, Ar), 5.07 
(s, 2H, -CH2), 3.91 (s, 3H, -CH3), 2.07 (br-s, 3H, adamantane-CH), 1.93–1.93 (br-d, 6H, adamantane-CH2), 
1.79–1.71 (br-q, 6H, adamantane-CH2); 13C-NMR (125 MHz, CDCl3): δ ppm 207.41 (C=O), 165.23 
(O-C=O), 159.52, 133.90, 132.21, 120.17, 119.19, 111.99 (Ar), 64.72 (-CH2), 56.03 (-CH3), 45.38, 
38.01, 36.48, 27.79 (adamantane-Cs). 
2-(Adamantan-1-yl)-2-oxoethyl 3-methoxybenzoate (2j): Solvent for growing crystal: acetone and ethanol 
(1: 1 v/v); Yield: 74%; M.P. 430–432 K; FTIR (ATR (solid) cm−1): 2926, 2853 (C–H, ν), 1711 (C=O, ν), 
1584, 1489 (Ar, C=C, ν), 1288, 1221, 1029 (C–O, ν), 759 (C–H, ω). 1H-NMR (500 MHz, CDCl3):  
δ ppm 7.70–7.68 (d, 1H, J = 8.0 Hz, Ar), 7.60 (s, 1H, Ar), 7.37–7.33 (t, 1H, J = 8.0 Hz, Ar), 7.13–7.11 
(m, 1H, Ar), 5.09 (s, 2H, -CH2), 3.85 (s, 3H, -CH3), 2.08 (br-s, 3H, adamantane-CH), 1.94–1.93 (br-d, 
6H, adamantane-CH2), 1.80–1.72 (br-q, 6H, adamantane-CH2); 13C-NMR (125 MHz, CDCl3): δ ppm 
207.18 (C=O), 165.96 (O-C=O), 159.56, 130.79, 129.42, 122.35, 120.04, 114.05 (Ar), 65.04 (-CH2), 
55.44 (-CH3), 45.39, 38.01, 36.46, 27.77 (adamantane-Cs). 
2-(Adamantan-1-yl)-2-oxoethyl 4-methoxybenzoate (2k): Solvent for growing crystal: acetone and 
ethanol (1: 1 v/v); yield: 80%; M.P. 390–392 K; FTIR (ATR (solid) cm−1): 2903, 2851 (C–H, ν), 1710 
(C=O, ν), 1605, 1417 (Ar, C=C, ν), 1253, 1167, 1028 (C–O, ν), 767 (C–H, ω); 1H-NMR (500 MHz, 
CDCl3): δ ppm 8.05–8.04 (d, 2H, J = 9.0 Hz, Ar), 6.93–6.91 (d, 2H, J = 9.0 Hz Ar), 5.07 (s, 2H,  
-CH2), 3.86 (s, 3H, -CH3), 2.08 (br-s, 3H, adamantane-CH), 1.93–1.93 (br-d, 6H, adamantane-CH2), 
1.80–1.72 (br-q, 6H, adamantane-CH2); 13C-NMR (125 MHz, CDCl3): δ ppm 207.54 (C=O), 165.77 
(O-C=O), 163.61, 131.96, 121.94, 113.66 (Ar), 64.73 (-CH2), 55.44 (-CH3), 45.39, 38.02, 36.47,  
27.79 (adamantane-Cs). 
2-(Adamantan-1-yl)-2-oxoethyl 2-nitrobenzoate (2l): Solvent for growing crystal: acetone, ethanol and 
acetonitrile (1:1:1 v/v/v); yield: 70%; M.P. 391–393 K; FTIR (ATR (solid) cm−1): 2919, 2850 (C–H, ν), 
1731 (C=O, ν), 1579, 1450 (Ar, C=C, ν), 1535, 1353 (N–O, ν), 1290, 1132, 1079 (C–O, ν), 732 (C–H, ω); 
1H-NMR (500 MHz, CDCl3): δ ppm 7.97–7.95 (d, 1H, J = 7.5 Hz, Ar), 7.94–7.92 (d, 1H, J = 7.5 Hz Ar), 
7.73–7.70 (t, 1H, J = 7.5 Hz, Ar), 7.66–7.63 (t, 1H, J = 7.5 Hz, Ar), 5.12 (s, 2H, -CH2), 2.09 (br-s, 3H, 
adamantane-CH), 1.92(br-s, 6H, adamantane-CH2), 1.78–1.74 (br-d, 6H, adamantane-CH2); 13C-NMR 
(125 MHz, CDCl3): δ ppm 206.75 (C=O), 164.97 (O-C=O), 147.74, 133.17, 131.78, 130.35, 127.46, 
123.94 (Ar), 65.92 (-CH2), 45.39, 37.95, 36.41, 27.72 (adamantane-Cs). 
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2-(Adamantan-1-yl)-2-oxoethyl 3-nitrobenzoate (2m): yield: 72%; M.P. 385–387 K; FTIR (ATR 
(solid) cm−1): 3092 (Ar, C–H, ν), 2917, 2851 (C–H, ν), 1727 (C=O, ν), 1631, 1421 (Ar, C=C, ν), 1533, 
1347 (N–O, ν), 1297, 1261, 1131 (C–O, ν), 716 (C–H, ω); 1H-NMR (500 MHz, CDCl3): δ ppm 8.92  
(s, 1H, Ar), 8.45–8.43 (d, 1H, J = 8.1 Hz, Ar), 8.42–8.40 (d, 1H, J = 8.1 Hz, Ar), 7.69–7.65 (t, 1H,  
J = 8.1 Hz, Ar), 5.17 (s, 2H, -CH2), 2.10 (br-s, 3H, adamantane-CH), 1.94 (br-s, 6H, adamantane-CH2), 
1.79–1.76 (br-d, 6H, adamantane-CH2); 13C-NMR (125 MHz, CDCl3): δ ppm 206.60 (C=O), 164.00 
(O-C=O), 148.31, 135.52, 131.35, 129.67, 127.66, 124.92 (Ar), 65.61 (-CH2), 45.39, 37.99, 36.42, 
27.74 (adamantane-Cs). 
2-(Adamantan-1-yl)-2-oxoethyl 4-nitrobenzoate (2n): Solvent for growing crystal: acetone, ethanol and 
acetonitrile (1:1:1 v/v/v); yield: 76%; M.P. 437–439 K; FTIR (ATR (solid) cm−1): 3112 (Ar, C–H, ν), 
2905, 2854 (C–H, ν), 1723 (C=O, ν), 1606, 1422 (Ar, C=C, ν), 1530, 1344 (N–O, ν), 1283, 1118  
(C–O, ν), 714 (C–H, ω); 1H-NMR (500 MHz, CDCl3): δ ppm 8.31–8.29 (d, 2H, J = 8.5 Hz, Ar),  
8.27–8.25 (d, 2H, J = 8.5 Hz Ar), 5.16 (s, 2H, -CH2), 2.10 (br-s, 3H, adamantane-CH), 1.94 (br-s, 6H, 
adamantane-CH2), 1.81–1.73 (br-q, 6H, adamantane-CH2); 13C-NMR (125 MHz, CDCl3): δ ppm 
206.61 (C=O), 164.21 (O-C=O), 150.72, 134.97, 131.00, 123.56 (Ar), 65.61 (-CH2), 45.40, 37.99, 
36.41, 27.73 (adamantane-Cs). 
2-(Adamantan-1-yl)-2-oxoethyl 2-aminobenzoate (2o): Solvent for growing crystal: acetone, ethanol 
and acetonitrile (1:1:1 v/v); yield: 76%; M.P. 440–442 K; FTIR (ATR (solid) cm−1): 3497, 3373 (N–H, ν), 
2902, 2848 (C–H, ν), 1695 (C=O, ν), 1613, 1418 (Ar, C=C, ν), 1581 (N–H, δ), 1243, 1104 (C–O, ν), 
746 (C–H, ω); 1H-NMR (500 MHz, CDCl3): δ ppm 7.95–7.94 (d, 1H, J = 8.3 Hz, Ar), 7.29–7.26  
(t, 1H, J = 8.3 Hz Ar), 6.67–6.64 (m, 2H, Ar), 5.07 (s, 2H, -CH2), 2.08 (br-s, 3H, adamantane-CH), 
1.93 (br-s, 6H, adamantane-CH2), 1.80–1.72 (br-d, 6H, adamantane-CH2); 13C-NMR (125 MHz, 
CDCl3): δ ppm 207.64 (C=O), 167.29 (O-C=O), 150.52, 134.38, 131.63, 116.67, 116.41, 110.34 (Ar), 
64.46 (-CH2), 45.38, 38.05, 36.47, 27.79 (adamantane-Cs). 
2-(Adamantan-1-yl)-2-oxoethyl 3-aminobenzoate (2p): Solvent for growing crystal: acetone, ethanol 
and acetonitrile (1:1:1 v/v/v); yield: 70%; M.P. 396–398 K; FTIR (ATR (solid) cm−1): 3465, 3347  
(N–H, ν), 2902, 2849 (C–H, ν), 1700 (C=O, ν), 1631, 1461 (Ar, C=C, ν), 1603 (N–H, δ), 1248, 1113 
(C–O, ν), 751 (C–H, ω); 1H-NMR (500 MHz, CDCl3): δ ppm 7.50–7.49 (d, 1H, J = 7.9 Hz, Ar), 7.42 
(s, 1H, Ar), 7.24–7.21 (t, 1H, J = 7.9 Hz, Ar), 6.91–6.89 (d, 1H, J = 7.9 Hz, Ar), 5.08 (s, 2H, -CH2), 
2.08 (br-s, 3H, adamantane-CH), 1.93–1.92 (br-d, 6H, adamantane-CH2), 1.79–1.72 (br-q, 6H, 
adamantane-CH2); 13C-NMR (125 MHz, CDCl3): δ ppm 207.36 (C=O), 166.17 (O-C=O), 145.98, 
130.49, 129.34, 120.42, 119.99, 116.28 (Ar), 64.91 (-CH2), 45.39, 38.00, 36.46, 27.77(adamantane-Cs). 
2-(Adamantan-1-yl)-2-oxoethyl 4-aminobenzoate (2q): yield: 76%; M.P. 428–430 K; FTIR (ATR 
(solid) cm−1): 3493, 3362 (N–H, ν), 2906, 2850 (C–H, ν), 1697 (C=O, ν), 1619, 1414 (Ar, C=C, ν), 
1600 (N–H, δ), 1276, 1118 (C–O, ν), 768 (C–H, ω); 1H-NMR (500 MHz, CDCl3): δ ppm 7.91–7.89  
(d, 2H, J = 8.5 Hz, Ar), 6.65–6.63 (d, 2H, J = 8.5 Hz, Ar), 5.04 (s, 2H, -CH2), 2.07 (br-s, 3H, 
adamantane-CH), 1.93–1.92 (br-d, 6H, adamantane-CH2), 1.79–1.71 (br-q, 6H, adamantane-CH2);  
13C-NMR (125 MHz, CDCl3): δ ppm 207.90 (C=O), 166.03 (O-C=O), 151.08, 132.00, 119.04, 113.92 
(Ar), 64.50 (-CH2), 45.57, 38.02, 36.60, 27.77 (adamantane-Cs). 
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2-(Adamantan-1-yl)-2-oxoethyl 2-pyridinecarboxylate (2r): Solvent for growing crystal: acetone, 
ethanol and acetonitrile (1:1:1 v/v/v); yield: 76%; M.P. 402–404 K; FTIR (ATR (solid) cm−1): 2903, 
2849 (C–H, ν), 1707 (C=O, ν), 1582, 1419 (Ar, C=C, ν), 1304 (C–N, ν) 1242, 1128 (C–O, ν), 745 (C–H, 
ω); 1H-NMR (500 MHz, CDCl3): δ ppm 8.79–8.78 (d, 1H, J = 4.7 Hz, Ar), 8.19–8.17 (d, 1H, J = 4.7 Hz, 
Ar), 7.88–7.86 (t, 1H, J = 4.7 Hz, Ar), 7.52–7.50 (q, 1H, J = 4.7 Hz, Ar), 5.20 (s, 2H, -CH2), 2.09 (br-s, 
3H, adamantane-CH), 1.93–1.93 (br-d, 6H, adamantane-CH2), 1.80–1.72 (br-q, 6H, adamantane-CH2); 
13C-NMR (125 MHz, CDCl3): δ ppm 206.36 (C=O), 164.54 (O-C=O), 149.86, 147.41, 137.12, 127.18, 
125.53 (Ar), 65.70 (-CH2), 45.31, 37.99, 36.44, 27.75 (adamantane-Cs). 
3.3. Bioactivity Methods 
3.3.1. Hydrogen Peroxide Radical Scavenging Assay 
The abilities of adamantyl-based compounds to scavenge hydroxyl radical were determined by 
following the method of [50] with some modifications. The solution of hydrogen peroxide (40 mM) 
was prepared in PBS (phosphate-buffered saline). The adamantyl-based derivatives with a concentration 
of 250 μg/mL were prepared in PBS and added to 0.6 mL of hydrogen peroxide solution. The mixture 
was mixed well and incubated at room temperature for 10 min. The absorbance was determined at  
230 nm by using a spectrophotometer. Ascorbic acid was used as a standard drug, while PBS was used 
as the blank. The percentage of hydrogen peroxide scavenging activity was calculated by using the 
following formula: 
100
control of Absorbance
sample of Absorbancecontrol of Absorbanceactivity scavenging  of Percentage ×−=  (1)
3.3.2. DPPH Radical Scavenging Assay 
The DPPH radical scavenging assay was used to evaluate the antioxidant properties of the 
adamantyl-based compounds. This assay was carried out following the method of [51]. The DPPH 
solution (0.16 mM) was prepared in ethanol. The adamantyl-based derivatives were prepared in ethanol 
with concentrations of 250, 500 and 1000 μg/mL. Approximately 100 μL of each adamantyl-based 
derivative were mixed with 100 μL of DPPH solution in a 96-well plate. Each sample and the control 
were prepared in triplicate. The plate was then incubated in a dark room at room temperature for  
30 min, and the absorbance was measured at 517 nm with a microplate reader. Ascorbic acid was used 
as a standard drug. The percentage of DPPH free radical scavenging activity was calculated by using 
the following formula: 
100
blankofAbsorbance
sample of Absorbanceblank of Absorbanceactivity scavenging  of Percentage ×−=  (2)
3.3.3. Protein Denaturation Assay 
Adamantyl-based compounds were tested on egg albumin to observe their anti-inflammatory activity 
against protein denaturation. The assay was performed following the method described by [52] with 
some modifications. The 2.5 mL of reaction mixture consisted of 0.1 mL of egg albumin, 1.4 mL of PBS 
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and 1 mL of adamantyl-based derivatives with a concentration of 250 μg/mL. A similar volume of PBS 
with egg albumin was used as the control. The mixture solutions were incubated at 37 °C for 15 min and 
then heat in a water bath at 70 °C for 5 min. After cooling to room temperature, the absorbance was 
measured at 660 nm using a microplate reader. Diclofenac sodium was used as the standard drug. The 
percentage of inhibition of protein denaturation was calculated by using the following formula: 
100
controlofAbsorbance
sample of Absorbancecontrol of Absorbanceactivity scavenging  of  Percentage ×−= (3)
4. Conclusions 
A series of 2-(adamantan-1-yl)-2-oxoethyl benzoates, 2(a–q), and 2-(adamantan-1-yl)-2-oxoethyl  
2-pyridinecarboxylate, 2r, were synthesized and structurally characterized by FTIR, NMR and  
single-crystal X-ray diffraction analysis. Introduction of the adamantane moiety into the synthesis of  
2-oxopropyl benzoate derivatives produced all molecular structures in synclinal conformation. In crystals, 
molecules are commonly packed in a head-to-tail (adamantane moiety to phenyl moiety) pattern. These 
similarities lead to redundant 2D or 3D structural similarity in adamantane-based ester derivatives. The 
adamantyl-based compounds show selective antioxidant abilities and good hydrogen peroxide radical 
scavenging activities, especially 2-(adamantan-1-yl)-2-oxoethyl 2-chlorobenzoate, which outperformed 
the standard compound. Besides that, three nitrogen-containing adamantane compounds, 2p, 2q and 2r, 
show strong anti-inflammatory effects towards protein denaturation, which performed better than 
diclofenac sodium. Thus, further modifications of adamantane compounds with nitrogen-containing 
groups can potentially produce promising anti-inflammatory agents for clinical use in the future. 
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